Should I buy Globus Medical (GMED) stock or is it too late?
⭐ The most reliable of them, either direction: Truist Securities — 64% of its targets hit on this sector (109 calls tested). It aims for $100 (+21 %), call made on July 17, 2026, maturing on July 17, 2027 (42 d ago).
Firm-by-firm track record on Globus Medical
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 100 % | +24.0 % | 5 | $80 -3% |
| Canaccord Genuity | 75 % | +17.9 % | 16 | $112 +36% |
| BTIG | 58 % | +14.3 % | 12 | $77 -7% |
| B of A Securities | 100 % | +12.9 % | 6 | $91 +10% |
| Wells Fargo | 62 % | +6.5 % | 13 | $99 +20% |
| Needham | 38 % | +4.7 % | 8 | $117 +42% |
| RBC Capital | 40 % | +3.3 % | 5 | $115 +39% |
| Morgan Stanley | 44 % | +1.6 % | 9 | $100 +21% |
✅ Reasons to believe
- 75% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
- Median price target $100, i.e. +21% from the current price ($83).
⚠️ Reasons to hesitate
- Even the most reliable firm on GMED, Stifel (100% hit rate, 5 scored calls), only targets $80 (call made on July 8, 2026, maturing on July 8, 2027) (-3%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 8 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on GMED
Median target $100 (+21%) · 8 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Globus Medical now?
We won't decide for you. The facts: 75% of analysts rate it a buy, median target $100 (+21%), and Stifel (most reliable on GMED, 100%) targets $80. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Globus Medical?
Not according to analysts: the median target ($100) is still +21% above the current price ($83) (most reliable on GMED: Stifel, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Globus Medical still worth investing in?
It depends on the gap between the price ($83) and its estimated value: analysts target $100 on median (+21%), with 75% buys (most reliable on GMED: Stifel, 100%). Cross-check with their real reliability on GMED and the cautions above. Information, not advice.
What's the main risk in buying GMED?
Even the most reliable firm on GMED, Stifel (100% hit rate, 5 scored calls), only targets $80 (call made on July 8, 2026, maturing on July 8, 2027) (-3%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Globus Medical profile (consensus, analyst reliability, price target, performance).